ERBB2 and breast carcinoma: Alpelisib, a selective phosphoinositide 3-kinase alpha (PI3Kα) inhibitor approved for hormone receptor-positive, HER2-negative, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3Cα)-mutated breast cancer, is frequently associated with dermatologic adverse effects.